BRIEF published on 06/16/2026 at 21:21, 3 months 10 days ago Medincell: Key Results and Initiatives for 2025-2026 Innovation Treasury R&D Royalties Medincell
PRESS RELEASE published on 06/16/2026 at 21:16, 3 months 10 days ago Informations privilégiées / Communiqué sur comptes, résultats Medincell publie ses résultats financiers annuels consolidés pour l'exercice 2025-2026, mettant en avant la solidité opérationnelle et la transition vers un modèle reposant sur l'innovation et les revenus récurrents Résultats Financiers Innovation Revenus Récurrents Medincell Exercice 2025-2026
BRIEF published on 05/21/2026 at 19:29, 4 months 5 days ago L'EMA accepte la demande de Teva pour un traitement de la schizophrénie à action prolongée Traitement De La Schizophrénie Teva Pharmaceuticals Approbation De L'EMA Olanzapine Injectable Formule À Action Prolongée
BRIEF published on 05/21/2026 at 19:29, 4 months 5 days ago EMA Accepts Teva's Application for Long-Acting Schizophrenia Treatment Schizophrenia Treatment Teva Pharmaceuticals EMA Approval Olanzapine Injectable Long-acting Formulation
PRESS RELEASE published on 05/21/2026 at 19:24, 4 months 5 days ago Informations privilégiées / Autres communiqués L'EMA accepte le dossier de demande de mise sur le marché de l'Olanzapine LAI par Teva pour le traitement de la schizophrénie. Technologie de libération prolongée SteadyTeq(TM) utilisée Schizophrénie Teva EMA Olanzapine LAI SteadyTeq
PRESS RELEASE published on 05/21/2026 at 19:24, 4 months 5 days ago Inside Information / Other news releases European Medicines Agency accepts Teva's Marketing Authorization Application for Olanzapine Long-Acting Injectable to treat schizophrenia in adults. Teva and Medincell announce EMA acceptance for innovative treatment option Schizophrenia Medincell Olanzapine Teva EMA
BRIEF published on 04/29/2026 at 13:44, 4 months 28 days ago Croissance impressionnante des ventes de UZEDY® au T1 2026 Schizophrénie Medincell Teva Pharmaceuticals UZEDY® Ventes T1 2026
BRIEF published on 04/29/2026 at 13:44, 4 months 28 days ago UZEDY® Q1 2026 Sales Surge by 62% FDA Approvals Olanzapine LAI UZEDY® Sales Teva Partnership Medincell Growth
BRIEF published on 04/29/2026 at 13:44, 4 months 28 days ago Impressive sales growth for UZEDY® in Q1 2026 Schizophrenia Medincell Teva Pharmaceuticals UZEDY® Q1 2026 Sales
BRIEF published on 04/29/2026 at 13:44, 4 months 28 days ago Les ventes d'UZEDY® au premier trimestre 2026 devraient bondir de 62 %. Olanzapine LAI Ventes UZEDY® Partenariat Avec Teva Approbations De La FDA Croissance De Medincell
Published on 09/26/2026 at 01:00, 1 day 15 hours ago Findev Inc. Provides Update on Victoria Park Loan Exposure and Expected Accounting Impairment
Published on 09/25/2026 at 22:15, 1 day 18 hours ago Rocky Shore Gold Closes First Tranche of Non-Brokered Private Placement
Published on 09/25/2026 at 17:30, 1 day 23 hours ago Goldcliff Announces Unit and Flow Through "LIFE" Offerings
Published on 09/25/2026 at 15:00, 2 days 1 hour ago HM Exploration Provides Program Update for the Lewis Pilley's Project
Published on 09/26/2026 at 15:30, 1 day 1 hour ago QUORRA X5 fait ses débuts mondiaux à REHACARE International 2026 en Allemagne
Published on 09/26/2026 at 15:30, 1 day 1 hour ago QUORRA X5 Makes Its Global Debut at REHACARE International 2026 in Germany
Published on 09/26/2026 at 15:15, 1 day 1 hour ago Timur Turlov Elected FIDE President, Becomes First Kazakh to Lead World Chess
Published on 09/26/2026 at 07:45, 1 day 8 hours ago Green SM Begins Pilot Operations In The Netherlands, Further Expanding Its Presence In Europe
Published on 09/26/2026 at 00:01, 1 day 16 hours ago Photon Energy N.V. Sells 7.6 MWp of PV Operational Assets in Slovakia
Published on 09/25/2026 at 17:45, 1 day 22 hours ago COGRA : ASSEMBLÉE GÉNÉRALE MIXTE DU 16 OCTOBRE 2026 / MISE À DISPOSITION DU RAPPORT FINANCIER ANNUEL 2025/2026
Published on 09/25/2026 at 17:40, 1 day 22 hours ago Availability of the 2026 half-year financial report
